Key points are not available for this paper at this time.
In this phase 2 trial, nemolizumab at all monthly doses significantly improved pruritus in patients with moderate-to-severe atopic dermatitis, which showed the efficacy of targeting interleukin-31 receptor A. The limited size and length of the trial preclude conclusions regarding adverse events. (Funded by Chugai Pharmaceutical; XCIMA ClinicalTrials.gov number, NCT01986933 .).
Building similarity graph...
Analyzing shared references across papers
Loading...
Ruzicka et al. (Wed,) studied this question.
www.synapsesocial.com/papers/69da7db10f32475823a3d5af — DOI: https://doi.org/10.1056/nejmoa1606490
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Thomas Ruzicka
Jon M. Hanifin
Masutaka Furue
New England Journal of Medicine
Kyoto University
Ludwig-Maximilians-Universität München
Oregon Health & Science University
Building similarity graph...
Analyzing shared references across papers
Loading...